Abstracts tagged "Patient reported outcomes"

Abstract Number: 1336 • ACR Convergence 2022
Productivity Analysis in Patients with Idiopathic Inflammatory Myopathies and Relationship with Quality of Life and Emotional Domain: Preliminary Data from a Monocentric Cohort
Chiara Cardelli¹, Michele Diomedi¹, Simone Barsotti¹, Alessandra Tripoli², Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Vecchiano, Italy
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) are chronic diseases often causing disability in patients, associated with both disease activity and damage accrual. These conditions might reduce…
Abstract Number: 1451 • ACR Convergence 2022
Delayed Sleep Phase Syndrome Characterizes Circadian Disorder in Patients with Active SLE
Christina Stankey¹, Philip Chu², Alicia Hinze³, Lily McMorrow¹, Alia El-Qunni¹, Deepali Sen¹, Seth Eisen¹, Yo-El Ju¹ and Alfred Kim¹, ¹Washington University School of Medicine, St. Louis, MO, ²Duke University Hospital, Raleigh, NC, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: Poor sleep quality is a common complaint of patients with SLE. Although chronic sleep disruption is known to drive circadian rhythm disorders, the effects…
Abstract Number: 1973 • ACR Convergence 2022
Association Between Activity Limitations, Sleep Disturbance, Pain Sensitivity, Pain Intensity, and Widespread Pain in Adults with Rheumatoid Arthritis
Burcu Aydemir¹, Jing Song², Lutfiyya Muhammad³, Daniela Grimaldi¹, Kathryn Reid¹, Phyllis Zee¹, Rowland Chang⁴ and Yvonne Lee¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Evanston, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Despite treatment with strong immunosuppressive medications, more than half of patients with rheumatoid arthritis (RA) still report pain. Pain can spread from joint sites…
Abstract Number: 2246 • ACR Convergence 2022
Rheumatoid Arthritis Patient Discordance with Provider Treatment Goals Is Associated with Poorer RA Outcomes
Kelly O'Neill¹, Pamela Sinicrope², Cynthia Crowson³, Kathryne Marks⁴, Rachel Giblon⁵, Elena Myasoedova² and John Davis², ¹Rheumatoid Patient Foundation, Winter Springs, FL, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: We previously reported on themes in rheumatoid arthritis (RA) patients' treatment goals which associated with aspects of rheumatology care such as presence of a…
Abstract Number: 0191 • ACR Convergence 2022
Patient-reported Outcomes to Assess Dyspnea in Connective Tissue Diseases, Interstitial Lung Disease and Pulmonary Hypertension, a Systematic Literature Review of Measurement Properties
Jacqueline Lemmers¹, Madelon Vonk² and Els Ende, van den³, ¹Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Radboudumc, Nijmegen, Netherlands
Background/Purpose: This COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN)-based systematic review aims to identify and summarize the quality of measurement properties of…
Abstract Number: 0314 • ACR Convergence 2022
Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
Vibeke Strand¹, Evgeny Nasonov², Tatiana Lisitsyna², Alexander Lila², Sofia Kuzkina³, Mikhail Samsonov⁴ and Eugen Feist⁵, ¹Stanford University School of Medicine, Stanford, CA, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³R-Pharm, Moscow, Russia, ⁴R-Pharm JSC, Moscow, Russia, ⁵Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany
Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of rheumatoid arthritis (RA). In these analyses we present patient reported outcomes (PROs) reported by TNF-IR patients…
Abstract Number: 0503 • ACR Convergence 2022
The Effect of Social Isolation on 1-Year Outcomes After Surgical Repair of Low Trauma Hip Fracture
Robyn Lipschultz¹, Dina Sheira¹, Marianna Frey², Mangala Rajan³, Joseph Lane¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²University of Rochester School of Medicine and Dentistry, New York, NY, ³Weill Cornell Medicine, New York, NY
Background/Purpose: Hip fractures are a serious public health issue with a significant population burden, especially among those over 65 years old. Social isolation—how integrated a…
Abstract Number: 0863 • ACR Convergence 2022
Effect of Glucocorticoids on Patient Reported Outcomes in Patients Started on a Biologic Consensus Treatment Plan for the ‘First Line Options for Systemic JIA Treatment’ (FROST) Study
Karen James¹, George Tomlinson², Tim Beukelman³, Laura Schanberg⁴, Anne Dennos⁵, VIncent Del Gaizo⁶, Marian Jelinek⁷, Erin Pfeifer⁸, Shalini Mohan⁹ and Yukiko Kimura¹⁰, ¹University of Utah, Salt Lake City, UT, ²University of Toronto, Toronto, ON, Canada, ³Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Childhood Arthritis and Rheumatology Research Alliance (CARRA), Durham, NC, ⁷Childhood Arthritis and Rheumatology Research Alliance (CARRA), Duke, ⁸Genentech, Englewood, NJ, ⁹Genentech, San Diego, ¹⁰Hackensack Meridian Health, New York, NY

Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a systemic autoinflammatory disease characterized by high fevers, rash and arthritis. Current treatment regimens often involve biologic (anti-IL-1…
Abstract Number: 1339 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
Matthew Wong-Pack¹, Elliot Hepworth², Mohammad Movahedi³, Bindee Kuriya¹, Janet Pope⁴, Edward Keystone⁵, Carter Thorne⁶, VANDANA AHLUWALIA⁷, Angela Cesta⁸, Carol Mously⁸, Claire Bombardier¹, Arthur Lau⁹ and Sibel Aydin¹⁰, ¹University of Toronto, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷William Osler Health System, Brampton, ON, Canada, ⁸University Health Network, Toronto, ON, Canada, ⁹McMaster University, Hamilton, ON, Canada, ¹⁰University of Ottawa, Rheumatology, Ottawa, Canada, Ottawa, ON, Canada
Background/Purpose: The COVID-19 Pandemic created challenges for patients with rheumatoid arthritis (RA), including accessing the health care system, transition to unplanned virtual care, reduction in…
Abstract Number: 1458 • ACR Convergence 2022
Systemic Lupus Erythematosus (SLE) Patients with Cognitive Impairment Experience More Fatigue Compared to Patients Without Impairment
Delansie Lawrence¹, Jiandong Su¹, Andrea Knight², Kathleen Bingham³, Mahta Kakvan¹, Maria Carmela Tartaglia⁴, Leslet Ruttan⁵, Joan Wither⁶, May Choi⁷, Simone Appenzeller⁸, Nicole Anderson¹, Dennisse Bonilla¹, Patricia Katz⁹, Dorcas Beaton¹⁰, Robin Green⁵, Zahi Touma¹ and Michelle Barraclough¹¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁸Unicamp, Campinas, São Paulo, Brazil, ⁹UCSF, San Rafael, CA, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is highly prevalent in patients with systemic lupus erythematosus (SLE). Objective prevalence rates are reported as 38% [range: 20% to 80%]…
Abstract Number: 1992 • ACR Convergence 2022
Burden of Pain for Patients in the CorEvitasTM Rheumatoid Arthritis Registry
Joshua Baker¹, J Morel Symons², Jud C Janak³, Page Moore³, Elizabeth Kohl³, Bernice Gershenson³, Oksana Pugach³, Dave Webb⁴, Alan A Martin⁴, Didier Saurigny⁵ and Marguerite Bracher⁵, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ²GlaxoSmithKline, Collegeville, PA, ³CorEvitas, LLC, Waltham, MA, ⁴GlaxoSmithKline, Brentford, United Kingdom, ⁵GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Pain is a hallmark symptom of RA that impacts patients' quality of life and informs therapeutic decisions that aim to reduce joint inflammation and…
Abstract Number: PP07 • ACR Convergence 2022
Remissions and Vigilance
Michael Scepaniak, Cockeysville, MD
Background/Purpose: I've been diagnosed with spondyloarthritis (SpA) for a little more than 7 1/2 years. That diagnosis was preceded by roughly 9 months of significant…
Abstract Number: 0192 • ACR Convergence 2022
Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
Laura Coates¹, Arthur Kavanaugh², Erin McDearmon-Blondell³, Arthur Mandelin⁴, Tianming Gao⁵ and William Tillett⁶, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ²University of California San Diego, La Jolla, CA, ³AbbVie, Inc., Mettawa, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵AbbVie, Inc., North Chicago, IL, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: RAPID3 (Routine Assessment of Patient Index Data 3) is a disease activity index calculated from 3 patient-reported measures: physical function, pain, and patient global…
Abstract Number: 0344 • ACR Convergence 2022
Therapeutic Thresholds of Hydroxychloroquine Blood Levels: Physiologic and Social Determinants of Low Hydroxychloroquine Blood Levels
Shivani Garg¹, Betty Chewning², Brad Astor³ and Christie Bartels⁴, ¹University of Madison, School of Medicine and Public Health, Madison, WI, ²University of Wisconsin, School of Pharmacy, Madison, WI, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Lupus, the leading cause of chronic kidney disease (CKD) in young women, is treated with Hydroxychloroquine (HCQ) which is primarily excreted by kidneys. Yet…
Abstract Number: 0523 • ACR Convergence 2022
The Development of the Ranked Composite Important Difference in Diffuse Cutaneous Systemic Sclerosis; A Clinical and Patient Meaningful Anchor to the ACR-Composite Response Index in SSc
Lesley-Anne Bissell¹, Daniel Furst², sindhu johnson³, Paul hansen⁴, Esmeralda Recalde⁵, Dinesh Khanna⁶ and Francesco Del Galdo⁷, ¹University of Leeds, Leeds, United Kingdom, ²University of California Los Angeles, Los Angeles, CA, ³Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁴University of Otago, Dunedin, New Zealand, ⁵World Scleroderma Foundation, Florence, Italy, ⁶Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: The ACR Composite Response Index in Systemic Sclerosis ( ACR-CRISS) is one of the first composite outcome measures in diffuse cutaneous Systemic sclerosis (dcSSc-…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].